Skip to main content

Advertisement

SpringerLink
Log in

Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention

  • Review
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

The aim of our study was to identify all previously reported cases of phenytoin- or fosphenytoin-associated purple glove syndrome (PGS) and summarize the most current understanding of the pathophysiology, clinical presentation, diagnosis, and treatment of the disease. We searched the English language references from MEDLINE, EMBASE, CINAHL, TOXNET, and gray literature that featured one or more case descriptions of phenytoin- or fosphenytoin-associated PGS after administration and provided information on the clinical setting of the event and associated outcome(s). Descriptive statistics were employed to summarize relevant facts about the cases. We identified 82 unique cases of parenteral phenytoin-associated PGS and 5 cases of fosphenytoin-associated PGS that were published from 1984 to 2015. Additionally, we found two cases of PGS associated with oral formulation of phenytoin published from 1999 to 2015. The spectrum of tissue injury ranged from mild local cutaneous reactions around the infusion site to frank limb ischemia. Just over a half of cases reported symptoms after one dose of IV phenytoin. Pathologic findings included evidence for microvascular thrombosis and possible microvascular or subclinical extravasation as a contributing mechanism. Dopper ultrasound and conventional angiography were used in some patients to identify arterial or venous thrombosis. Various treatments were documented including the use of supportive care such as limb elevation and heat or cold application, utilization of systemic antibiotics, anticoagulants, or vasodilators, and local infiltration of hyaluronidase, heparin, or other compounds. In a small number of patients, invasive interventions such as regional anesthesia, thrombectomy, fasciotomy, and debridement were described. Time to resolution varied from days to weeks. Resolution of PGS without deficits was documented in the majority of cases. Skin changes followed by sensory and motor deficits were described in 16, 6, and 5 cases, respectively. Four patients underwent skin grafting and eight patients required limb amputation. Death as a result of PGS was documented in two patients. PGS associated with oral and injectable phenytoin or parenteral fosphenytoin has been documented in the literature and sometimes includes significant vascular thrombosis and potentially limb-threatening ischemia. Avoidance of small hand veins, adherence to recommended IV administration guidelines and monitoring of the infusion site for reactions should be considered to decrease the morbidity of IV phenytoin or fosphenytoin use. Patients with PGS and evidence of decreased distal perfusion should undergo prompt vascular imaging and potential intervention to avoid ischemic sequelae. Alternative anticonvulsant drugs should be considered in patients at risk for PGS when possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parenteral Dilantin (Phenytoin Sodium Injection, USP) [prescribing information]. Revised February 2013. Parke Davis: New York. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010151s037lbl.pdf. Accessed 6 June 2015.

  2. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

    Article  CAS  PubMed  Google Scholar 

  3. Cerebyx (Fosphenytoin Sodium Injection) [prescribing information]. Pfizer Labs: New York. Revised April 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=749. Accessed 6 June 2015.

  4. Comer J. Extravasation from intravenous phenytoin. Am J Intraven Ther Clin Nutr. 1984;11:23–9.

    Google Scholar 

  5. Hanna D. Purple glove syndrome: a complication of intravenous phenytoin. J Neurosci Nurs. 1992;24(6):340–5.

    Article  CAS  PubMed  Google Scholar 

  6. Intravenous Phenytoin and Fosphenytoin Safety Concerns Background Package. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm231776.pdf. Accessed 6 June 2015.

  7. Brophy G, Bell R, Claassen J, Alldredge B, Bleck T, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.

    Article  PubMed  Google Scholar 

  8. Huff J, Melnick E, Tomaszewski C, Thiessen M, Jagoda A, Fesmire F. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med. 2014;63(4):437–447.e15.

    Article  PubMed  Google Scholar 

  9. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, et al. Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma. 2007;24 Suppl 1:S83–6.

    Google Scholar 

  10. Shorvon S, Baulac M, Cross H, Trinka E, Walker M, et al. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London colloquium on status epilepticus. Epilepsia. 2008;49(7):1277–85.

    PubMed  Google Scholar 

  11. Birbeck GL, French JA, Perucca E, Simpson DM, Fraimov H, George JM, et al. Evidence-based guidelins: antiepileptic drug selection for people with HIV/AIDS: report of the quality standards subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78(2):139–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Summary of information about Purple Glove Syndrome in association with intravenous administration of phenytoin and fosphenytoin. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM231777.pdf. Accessed 6 June 2015.

  13. Chhabra P, Gupta N, Kaushik A. Compartment syndrome as a spectrum of purple glove syndrome following intravenous phenytoin administration in a young male: a case report and review of literature. Neurol India. 2013;61(4):419–20.

    Article  PubMed  Google Scholar 

  14. Jain RS, Nagpal K, Kumar S, Prakash S, Handa R. Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma. Am J Emerg Med. 2015;33(1):123.e5–6.

    Article  Google Scholar 

  15. Helfaer M, Ware C. Purple glove syndrome. J Neurosurg Anesthesiol. 1994;6(1):48–9.

    Article  CAS  PubMed  Google Scholar 

  16. Sharief N, Goonasekera C. Soft tissue injury associated with intravenous phenytoin in a neonate. Acta Paediatr. 1994;83(11):1218–9.

    Article  CAS  PubMed  Google Scholar 

  17. Bhattacharjee P, Glusac E. Early histopathologic changes in purple glove syndrome. J Cutan Pathol. 2004;31(7):513–5.

    Article  PubMed  Google Scholar 

  18. Santoshi J, Justin A, Jacob J, Pallapati S, Thomas B. Purple glove syndrome: a case report. Hand surgeons and physicians be aware. J Plast Reconstr Aesthet Surg: JPRAS. 2010;63(3):e340–2.

    Article  PubMed  Google Scholar 

  19. Sonohata M, Asami A, Tsunoda K, Hotokebuchi T. Purple glove syndrome associated with intravenous phenytoin administration in a patient with severe mental and motor retardation. J Orthop Sci. 2006;11(4):409–11.

    Article  PubMed  Google Scholar 

  20. Hayes A, Chesney T. Necrosis of the hand after extravasation of intravenously administered phenytoin. J Am Acad Dermatol. 1993;28(6):360–3.

    Article  CAS  PubMed  Google Scholar 

  21. Hunt S. Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Am J Dermatopathol. 1995;17(4):399–402.

    CAS  PubMed  Google Scholar 

  22. O’Brien T, Cascino G, So E, Hanna D. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51(4):1034–9.

    Article  PubMed  Google Scholar 

  23. Spengler R, Arrowsmith J, Kilarski D, Buchanan C, Von Behren L, Graham D. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch Intern Med. 1988;148(6):1329–33.

    Article  CAS  PubMed  Google Scholar 

  24. Jamerson B, Dukes G, Brouwer K, Donn K, Messenheimer J, Powell J. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacother: J Hum Pharmacol Drug Ther. 1994;14(1):47–52.

    CAS  Google Scholar 

  25. Doellman D, Hadaway L, Bowe-Geddes L, Franklin M, LeDonne J, Parke-O’Donnell L, et al. Infiltration and extravasation. Update on prevention and management. J Infus Nurs. 2009;32(4):203–11.

    Article  PubMed  Google Scholar 

  26. Hannon M, Lee S. Extravasation injuries. J Hand Surg. 2011;36A:2060–5.

    Article  Google Scholar 

  27. Sokol D, Dahlmann A, Dunn D. Hyaluronidase treatment for intravenous phenytoin extravasation. J Child Neurol. 1998;13(5):246–7.

    Article  CAS  PubMed  Google Scholar 

  28. Prince N, Hill C. Purple glove syndrome following intravenous phenytoin administration. Arch Dis Child. 2011;96(8):734.

    Article  CAS  PubMed  Google Scholar 

  29. Prasad R, Mishra O, Gupta A. Gangrene of left hand following accidental intra-arterial injection of phenytoin sodium. Pediatric Oncall [serial online] 2012. doi: 10.7199/ped.oncall.2012.28.

  30. Sintenie J, Tuinebreijer W, Kreis R, Breederveld R. Digital gangrene after accidental intra-arterial injection of phenytoin (Epanutin). Eur J Surg. 1992;158(5):315–6.

    CAS  PubMed  Google Scholar 

  31. Mahajan R, Batra Y, Rajeev S. Intravenous phenytoin and percutaneous arterial cannulation: the purple-glove syndrome. Eur J Anaesthesiol. 2007;24(10):900–1.

    Article  CAS  PubMed  Google Scholar 

  32. Edwards J, Bosek V. Extravasation injury of the upper extremity by intravenous phenytoin. Anesth Analg. 2002;94(3):672–3.

    Article  PubMed  Google Scholar 

  33. Hagan 3rd H, Hastings H. Extravasation of phenytoin in the hand. J Hand Surg - Am. 1988;13(6):942–3.

    Article  PubMed  Google Scholar 

  34. Snelson C, Dieckman B. Recognizing and managing purple glove syndrome. Crit Care Nurse. 2000;20(3):54–61.

    CAS  PubMed  Google Scholar 

  35. Singh G, Cherian V, Thomas B. Low-concentration, continuous brachial plexus block in the management of purple glove syndrome: a case report. J Med Case Rep. 2010. doi:10.1186/1752-1947-4-48.

    Google Scholar 

  36. Twardowschy C, De Paola L, Germiniani F, Werneck LC, Silvado C. Pearls & oy-sters: soft-tissue necrosis as a result of intravenous leakage of phenytoin. Neurology. 2009;73(19):e94–5.

    Article  CAS  PubMed  Google Scholar 

  37. Chokshi R, Openshaw J, Mehta N, Mohler 3rd E. Purple glove syndrome following intravenous phenytoin administration. Vasc Med. 2007;12(1):29–31.

    Article  PubMed  Google Scholar 

  38. Senthilkumaran S, Balamurgan N, Suresh P, Phirumalaikolundusubramanian P. Purple glove syndrome: a looming threat. J Neurosci Rural Pract. 2010;1(2):121–2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Lalla R, Malhotra H, Garg R, Sahu R. Purple glove syndrome: a dreadful complication of intravenous phenytoin administration. BMJ Case Rep. 2012. doi:10.1136/bcr-2012-006653.

    Google Scholar 

  40. Burneo J, Anandan J, Barkley G. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42(9):1156–9.

    Article  CAS  PubMed  Google Scholar 

  41. Grinder D, Guastella CP, Pellegrino M. Soft-tissue damage and intravenous phenytoin. Drug Intell Clin Pharm. 1988;22(9):725–6.

    CAS  PubMed  Google Scholar 

  42. Fishel M, Sauer S, Allen J. When you give phenytoin i.v. RN. 1990;53(9):58–9.

    CAS  PubMed  Google Scholar 

  43. Cadenbach A, Rottger K, Muller M. “Purple glove syndrome.” Severe soft tissue reaction following phenytoin infusion. Dtsch Med Wochenschr. 1998;123(11):318–22.

    Article  CAS  PubMed  Google Scholar 

  44. Scumpia A, Yahsou J, Cajina J, Cao C. Purple glove syndrome after intravenous phenytoin administration presenting in the emergency department. J Emerg Med. 2013;44(2):e281–3.

    Article  PubMed  Google Scholar 

  45. McLean C, Cheng K, Clifton M. Fatal case of accidental intra-arterial phenytoin injection. Eur J Vasc Endovasc Surg. 2002;23(4):378–9.

    Article  CAS  PubMed  Google Scholar 

  46. Rao V, Feldman P, Dibbell D. Extravasation injury to the hand by intravenous phenytoin. Report of three cases. J Neurosurg. 1988;68(6):967–9.

    Article  CAS  PubMed  Google Scholar 

  47. Kasdan M, June L. Extravasation of phenytoin and diazepam requiring surgical debridement and skin grafting. Orthopedics. 1993;16(12):1355–7.

    CAS  PubMed  Google Scholar 

  48. Marders J. Sounding the alarm for I.V. infiltration. Nursing. 2005;35(4):18–20.

    Article  PubMed  Google Scholar 

  49. Weinstein M. Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med. 1989;149(8):1905.

    Article  CAS  PubMed  Google Scholar 

  50. Keane M, Shirazi H, Marsh P, Khushal A. Purple glove syndrome following intravenous phenytoin infusion. Br J Surg. 2009;96(9):1065.

    Google Scholar 

  51. Kirsch S, Bayard M, Darraj K. Distal upper extremity edema and discoloration. Am Fam Physician. 2007;75(6):889–91.

    PubMed  Google Scholar 

  52. Rajabally H, Nageshwaran S, Russell S. An atypical case of purple glove syndrome: an avoidable adverse event. BMJ Case Reports. 2012. doi:10.1136/bcr.01.2012.5653.

    PubMed Central  PubMed  Google Scholar 

  53. Kilarski D, Buchanan C, Von Behren L. Soft-tissue damage associated with intravenous phenytoin. N Engl J Med. 1984;311(18):1186–7.

    CAS  PubMed  Google Scholar 

  54. McDonnell P. Purple glove syndrome. PA PSRS Patient Saf Advis. 2006;3(4):12–3. Available at: http://patientsafetyauthority.org/ADVISORIES/AdvisoryLibrary/2006/Dec3%284%29/documents/12.pdf . Accessed 6 June 2015.

  55. Earnest M, Marx J, Drury L. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA. 1983;249(6):762–5.

    Article  CAS  PubMed  Google Scholar 

  56. Phenytoin sodium injection, USP [prescribing information]. Hospira Inc: Lake Forrest. Revised November 2010. http://www.hospira.com/Images/EN-2681_81-5775_1.pdf. Accessed 6 June 2015.

  57. Phenytoin Sodium Injection, USP [prescribing information]. West-Ward Pharmaceutical Corps: Eatontown. Revised April 2015. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=035a8d4e-2063-4240-83cb-d7eebcabe301. Accessed 6 June 2015.

  58. Phenytoin sodium injection, USP [prescribing information]. X-Gen Pharmaceuticals. Big Flats: NY. Revised February 2011. http://x-gen.us/wp-content/uploads/2014/03/phenytoin_pi.pdf. Accessed 6 June 2015.

  59. Beaulieu M. Hyaluronidase for extravasation management. Neonatal Netw - J Neonatal Nurs. 2012;31(6):413–8.

    Article  Google Scholar 

  60. Inaba K, Menaker J, Branco B, Gooch J, Okoye O, Herrold J, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013;74(3):766–71.

    Article  CAS  PubMed  Google Scholar 

  61. Yoshikawa H, Abe T, Oda Y. Purple glove syndrome caused by oral administration of phenytoin. J Child Neurol. 2000;15(11):762.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interest.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Lyudmila A. Garbovsky

  2. Division of Medical Toxicology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Jeanmarie Perrone

  3. Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Byron C. Drumheller & Jeanmarie Perrone

Authors
  1. Lyudmila A. Garbovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Byron C. Drumheller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeanmarie Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Byron C. Drumheller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garbovsky, L.A., Drumheller, B.C. & Perrone, J. Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention. J. Med. Toxicol. 11, 445–459 (2015). https://doi.org/10.1007/s13181-015-0490-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-015-0490-z

Keywords

Search

Navigation